US-UK Research Alliance Targets Global Health Threats

BIRMINGHAM, Ala. – February 03, 2026 – In a significant move to accelerate the global fight against infectious diseases and cancer, U.S.-based Southern Research has forged a three-year strategic partnership with London-based Pathogenus Consulting. The collaboration, which began in January, is designed to bridge continents by linking the American nonprofit's advanced research infrastructure with Pathogenus's extensive commercial and scientific network across Europe.

This alliance aims to capitalize on what insiders describe as accelerating global investment in biomedical research. It will provide international biotechnology companies with streamlined access to Southern Research's highly specialized preclinical testing services. The partnership's primary focus will be on developing treatments for pressing global health challenges, including respiratory viruses like influenza, RSV, and COVID-19, as well as other viral threats such as Dengue fever and the institute's longstanding focus on cancer.

“As global investment in research accelerates, this collaboration ensures we remain at the forefront of innovation that can improve health worldwide in the fight against emerging and re-emerging diseases,” said Fusataka Koide, senior director of global client engagement for Southern Research, in a statement announcing the deal.

A Strategic Push into the European Market

For Southern Research, an 80-year-old nonprofit with 200 scientists and a storied history in drug discovery, the partnership represents a calculated and significant expansion of its global footprint. While the organization has a strong reputation within the United States, this move signals a concerted effort to become a key player in the thriving European biotech ecosystem.

The groundwork for this type of international expansion has been laid before. In 2019, Southern Research established a similar partnership with Ina Research to bolster its presence in Japan, leveraging Ina's network of nearly 100 pharmaceutical companies. The new alliance with Pathogenus Consulting is a far more ambitious push into the West, targeting the dense concentration of pharmaceutical and biotech firms in the U.K., Ireland, Belgium, Switzerland, and the Netherlands.

Fusataka Koide noted the organization has already seen “clear momentum in our work with partners outside the United States, especially with Japan and European pharmaceutical companies.” This new alliance is designed to convert that momentum into market leadership. By embedding with Pathogenus, Southern Research is not just seeking clients; it is strategically positioning itself within the European R&D pipeline, gaining access and insights that would be difficult to achieve from its headquarters in Alabama alone.

Combining Infrastructure with Market Access

The synergy of the partnership lies in its clear division of expertise. Southern Research brings to the table its formidable scientific infrastructure and a deep well of institutional knowledge. This includes its high-containment Biosafety Level 2 (BSL-2) and Biosafety Level 3 (BSL-3) laboratories—critical and highly regulated facilities necessary for studying dangerous pathogens like influenza and SARS-CoV-2. These labs represent a significant capital investment and a level of expertise that smaller biotech firms and even some larger organizations cannot easily replicate.

Pathogenus Consulting, in turn, provides the essential 'last-mile' connection. Formed by veterans from the pharmaceutical and contract research organization (CRO) sectors, the consultancy specializes in market penetration and business development. Its role is to act as a facilitator, identifying European and international companies whose drug or vaccine candidates could benefit from Southern Research's preclinical models and assays.

“Pathogenus Consulting Limited is delighted to have this opportunity to work with an established and well-respected provider of preclinical models and assays,” said Adrian Wildfire, CEO of Pathogenus. “Southern Research has invested to excel in early-phase safety and efficacy testing with capabilities and capacity to match. Pathogenus offers expert business development skills and marketing know-how to help Southern Research bring its models directly to clients and to grow its market-share.”

A New Model for Scientific Collaboration

This partnership model is indicative of a broader trend in the global research landscape, where collaboration is increasingly seen as essential for tackling complex scientific challenges. While academic partnerships and large-scale corporate mergers are common, this alliance represents a more nimble and targeted approach. It pairs a mission-driven, nonprofit research engine with a commercially focused, agile consultancy to achieve mutual goals.

The arrangement allows Southern Research to extend its reach without the immense cost and complexity of building its own full-scale business development and marketing teams across Europe. For Pathogenus, it provides its network with a direct line to one of America's premier preclinical research facilities, enhancing its value proposition to biotech clients who are in a constant race to move promising candidates from the lab toward clinical trials.

The initial three-year term suggests a period of intense, focused activity where both parties must demonstrate tangible results. If successful, the potential to renew the agreement could solidify this trans-Atlantic bridge, creating a durable and effective pipeline for translating scientific discovery into life-saving therapies for years to come.